Sarepta Therapeutics, Inc. (FRA:AB3A)

Sarepta Therapeutics Statistics

Total Valuation

FRA:AB3A has a market cap or net worth of EUR 1.78 billion. The enterprise value is 2.13 billion.

Market Cap	1.78B
Enterprise Value	2.13B

Important Dates

The next estimated earnings date is Wednesday, February 25, 2026.

Earnings Date	Feb 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	104.79M
Shares Outstanding	n/a
Shares Change (YoY)	-2.62%
Shares Change (QoQ)	-5.99%
Owned by Insiders (%)	4.70%
Owned by Institutions (%)	85.35%
Float	99.78M

Valuation Ratios

PE Ratio	n/a
Forward PE	9.74
PS Ratio	0.86
PB Ratio	1.58
P/TBV Ratio	1.62
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 26.38, with an EV/FCF ratio of -6.56.

EV / Earnings	-9.20
EV / Sales	1.03
EV / EBITDA	26.38
EV / EBIT	n/a
EV / FCF	-6.56

Financial Position

The company has a current ratio of 2.95, with a Debt / Equity ratio of 0.95.

Current Ratio	2.95
Quick Ratio	1.51
Debt / Equity	0.95
Debt / EBITDA	13.43
Debt / FCF	-3.31
Interest Coverage	-3.95

Financial Efficiency

Return on equity (ROE) is -21.37% and return on invested capital (ROIC) is -2.06%.

Return on Equity (ROE)	-21.37%
Return on Assets (ROA)	-1.52%
Return on Invested Capital (ROIC)	-2.06%
Return on Capital Employed (ROCE)	-3.34%
Revenue Per Employee	1.50M
Profits Per Employee	-168,667
Employee Count	1,372
Asset Turnover	0.68
Inventory Turnover	2.40

Taxes

In the past 12 months, FRA:AB3A has paid 16.47 million in taxes.

Income Tax	16.47M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -85.23% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-85.23%
50-Day Moving Average	17.47
200-Day Moving Average	32.86
Relative Strength Index (RSI)	58.85
Average Volume (20 Days)	463

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.16

Income Statement

In the last 12 months, FRA:AB3A had revenue of EUR 2.06 billion and -231.41 million in losses. Loss per share was -2.36.

Revenue	2.06B
Gross Profit	378.28M
Operating Income	-73.30M
Pretax Income	-214.94M
Net Income	-231.41M
EBITDA	-30.92M
EBIT	-73.30M
Loss Per Share	-2.36

Balance Sheet

The company has 725.30 million in cash and 1.07 billion in debt, giving a net cash position of -348.90 million.

Cash & Cash Equivalents	725.30M
Total Debt	1.07B
Net Cash	-348.90M
Net Cash Per Share	n/a
Equity (Book Value)	1.13B
Book Value Per Share	10.74
Working Capital	1.53B

Cash Flow

In the last 12 months, operating cash flow was -208.51 million and capital expenditures -116.31 million, giving a free cash flow of -324.81 million.

Operating Cash Flow	-208.51M
Capital Expenditures	-116.31M
Free Cash Flow	-324.81M
FCF Per Share	n/a

Margins

Gross margin is 18.39%, with operating and profit margins of -3.56% and -11.25%.

Gross Margin	18.39%
Operating Margin	-3.56%
Pretax Margin	-10.45%
Profit Margin	-11.25%
EBITDA Margin	-1.50%
EBIT Margin	-3.56%
FCF Margin	n/a

Dividends & Yields

FRA:AB3A does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	2.62%
Shareholder Yield	2.62%
Earnings Yield	-13.02%
FCF Yield	-18.27%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 12, 2012. It was a reverse split with a ratio of 0.1666666667.

Last Split Date	Jul 12, 2012
Split Type	Reverse
Split Ratio	0.1666666667

Scores

FRA:AB3A has an Altman Z-Score of 1.28 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.28
Piotroski F-Score	3